Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs Baxter International Inc (BAX) Price & Performance

Baxter International IncTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs Baxter International Inc — how do they compare? AXT Inc trades at $79.85 (market cap $4.83B), while Baxter International Inc trades at $27.61 (market cap $14.36B). The key difference: Baxter International Inc is far larger — about 3× AXT Inc's market cap, and Baxter International Inc pays a 0.14% dividend while AXT Inc pays none. Which is the better fit depends on your goals.

AXTIBAX
Market Cap
$4.83B$14.36B
Sector
TechnologyHealth
52-Week High
$140.83$28.35
52-Week Low
$2.05$15.80
Enterprise Value
$4.50B$21.88B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI trades at $88.58, up 17.84% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat. The stock is technically bullish with support at $82 and resistance at $92. Fundamentally, revenue grew to $126 million in 2026 with a net profit margin of 3.23%, though valuation ratios like P/E of 2,460.33 appear elevated. Recent news highlights surging indium phosphide demand driven by AI data centers.

Outlook is positive with analyst consensus at Buy (72.73%) and a $72.50 price target, but risks include high valuation, cash flow volatility, and dependence on AI-driven demand. The stock offers growth exposure to semiconductor substrates, yet investors should weigh profitability sustainability against rich multiples.

Baxter International Inc

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX